SG11202007739XA - Arginase inhibitors and methods of use thereof - Google Patents

Arginase inhibitors and methods of use thereof

Info

Publication number
SG11202007739XA
SG11202007739XA SG11202007739XA SG11202007739XA SG11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA
Authority
SG
Singapore
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
SG11202007739XA
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Jianyan Wang
Steve Cook
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202007739XA publication Critical patent/SG11202007739XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007739XA 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof SG11202007739XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (fr) 2018-02-17 2019-02-15 Inhibiteurs de l'arginase et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11202007739XA true SG11202007739XA (en) 2020-09-29

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007739XA SG11202007739XA (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Country Status (22)

Country Link
US (3) US11420984B2 (fr)
EP (1) EP3752251A1 (fr)
JP (2) JP7317841B2 (fr)
KR (1) KR102657919B1 (fr)
CN (3) CN117180290A (fr)
AU (2) AU2019221896B2 (fr)
BR (1) BR112020015973A2 (fr)
CA (1) CA3091365A1 (fr)
CL (1) CL2020002096A1 (fr)
CR (1) CR20200418A (fr)
DO (1) DOP2020000145A (fr)
EC (1) ECSP20058183A (fr)
IL (1) IL276711B1 (fr)
JO (1) JOP20200197A1 (fr)
MA (1) MA51837A (fr)
MX (1) MX2020008570A (fr)
NI (1) NI202000055A (fr)
PE (1) PE20210176A1 (fr)
SG (1) SG11202007739XA (fr)
TW (1) TWI803574B (fr)
UY (1) UY38096A (fr)
WO (1) WO2019159120A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117180290A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN117903140A (zh) 2018-02-27 2024-04-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
US10851099B2 (en) 2018-03-29 2020-12-01 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CA3109100A1 (fr) 2018-08-22 2020-02-27 Astrazeneca Ab Inhibiteurs de l'arginase et leurs methodes d'utilisation
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220409642A1 (en) 2019-11-04 2022-12-29 Astrazeneca Ab Combination therapy for treating cancer
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162535A (en) 2010-04-22 2017-06-15 Mars Inc Inhibitors of arginase and their therapeutic applications
CN103249737B (zh) 2010-10-26 2016-06-08 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐
EP2658580A4 (fr) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc Inhibiteurs de l'arginase et leurs procédés d'utilisation
US9200011B2 (en) * 2012-04-18 2015-12-01 Mars, Incorporated Ring constrained analogs as arginase inhibitors
KR20180021117A (ko) * 2015-06-23 2018-02-28 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 활성 억제를 위한 조성물 및 방법
SG10202003966RA (en) 2015-10-30 2020-06-29 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
KR20190104521A (ko) * 2016-11-08 2019-09-10 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 억제제 병용 요법들
TWI818902B (zh) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
WO2019120296A1 (fr) 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de l'arginase
CN117180290A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US20210040127A1 (en) 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (fr) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation
EP3810615A4 (fr) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation

Also Published As

Publication number Publication date
ECSP20058183A (es) 2020-10-30
KR20200122341A (ko) 2020-10-27
TW201945004A (zh) 2019-12-01
AU2019221896B2 (en) 2022-03-24
TWI803574B (zh) 2023-06-01
US11912727B2 (en) 2024-02-27
DOP2020000145A (es) 2020-09-15
KR102657919B1 (ko) 2024-04-15
US20230122859A1 (en) 2023-04-20
JOP20200197A1 (ar) 2020-08-16
AU2019221896A1 (en) 2020-10-01
NZ767738A (en) 2023-12-22
PE20210176A1 (es) 2021-01-29
BR112020015973A2 (pt) 2020-12-15
CN111712302A (zh) 2020-09-25
JP2023145557A (ja) 2023-10-11
CN117186134A (zh) 2023-12-08
CN117180290A (zh) 2023-12-08
AU2022203938B2 (en) 2024-02-01
CA3091365A1 (fr) 2019-08-22
IL276711A (en) 2020-09-30
MX2020008570A (es) 2020-09-21
WO2019159120A1 (fr) 2019-08-22
US20210002305A1 (en) 2021-01-07
EP3752251A1 (fr) 2020-12-23
CN111712302B (zh) 2023-09-19
US11420984B2 (en) 2022-08-23
JP7317841B2 (ja) 2023-07-31
JP2021513964A (ja) 2021-06-03
UY38096A (es) 2019-07-31
NI202000055A (es) 2021-06-22
AU2022203938A1 (en) 2022-06-23
CL2020002096A1 (es) 2020-12-18
US20230365599A1 (en) 2023-11-16
MA51837A (fr) 2021-06-16
CR20200418A (es) 2020-10-27
IL276711B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
IL276711A (en) Arginase inhibitors and methods of using them
IL287940A (en) fgfr inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL283592A (en) Apol1 inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
EP3765006A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
IL287973A (en) acss2 inhibitors and methods of their use
IL284640A (en) PCSK9 inhibitors and methods of using them
EP3810615A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
IL284661A (en) pcsk9 inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3897622A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
IL278989A (en) MASP-2 suppressors and methods of using them
IL280924A (en) Arginase inhibitors and methods of using them
EP3986894A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3959197A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
IL286149A (en) Caspase inhibitors and methods of using them
IL286485A (en) pi4-kinase inhibitors and methods of using them
EP3793552C0 (fr) Inhibiteurs d'abhd12 et leurs procédés de fabrication et d'utilisation
IL285108A (en) Arginase inhibitors and methods of using them
EP4077332A4 (fr) Inhibiteurs de lin28 et leurs méthodes d'utilisation
EP3787630A4 (fr) Inhibiteurs de ferrochelatase et procédés d'utilisation